They are tisagenlecleucel (tisa-cel, Novartis: refractory and relapsed (r/r) B-ALL, r/r DLBCL, CD19-41BB-CD3z CAR-T, cryopreserved PBMC), axicabtagene ciloleucel (axi-cel, Kite Pharma: r/r DLBCL, CD19-CD28-CD3z CAR T, fresh PBMC), brexucabtagene autoleucel (brex-cel, Kite Pharma: r/r mantle cell lymphoma, CD19-CD28-CD3z CAR T, enriched T cell), lisocabtagene maraleucel (liso-cel, Juno Therapeutics & Bristol Myers Squibb: r/r DLBCL, CD19-41BB-CD3z CAR T, 1:1 mixture of CD4:CD8 T cell), and idecabtagene vicleucel (ide-cel, Bristol Myers Squibb: r/r MM, BCMA-41BB-CD3z CAR T, CD8 T cell) [5]. This evidence concerns the gene CD8A and Miyoshi myopathy.